Pharmacokinetics and dose response of anti-TB drugs in rat infection model of tuberculosis

Tuberculosis

Volumn 94, Issue 3, 2014, Pages 282-286

  Kumar, Naveen ^a   Vishwas, K G ^a   Kumar, Mahesh ^a   Reddy, Jitendar ^a   Parab, Manish ^a   Manikanth, C L ^a   Pavithra, B S ^a   Shandil, R K ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Front line TB drugs; Phamacokinetics; PK PD; Rat infection model; Tuberculosis

Indexed keywords

CARBOXYMETHYLCELLULOSE; ETHAMBUTOL; HYDROXYPROPYLMETHYLCELLULOSE; ISONIAZID; POLYSORBATE 80; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACILLI; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM COLONY; BLOOD SAMPLING; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; IN VIVO STUDY; INOCULATION; LUNG HOMOGENATE; LUNG TUBERCULOSIS; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; RAT MODEL; TREATMENT DURATION; ANIMAL; DRUG EFFECTS; DRUG SCREENING; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; WISTAR RAT;

ANIMALS; ANTITUBERCULAR AGENTS; BACTERIAL LOAD; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; MALE; MYCOBACTERIUM TUBERCULOSIS; RATS, WISTAR; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84900807427     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2014.02.004     Document Type: Article

References (32)

1. World Health Organization. Multidrug and extensive drug resistant tuberculosis 2010, global report on surveillance and response.
2. J.L. Flynn, A.M. Cooper, and W. Bishai Animal models of tuberculosis in the book tuberculosis and the tubercle bacilli S.T. Cole, K.D. Eisenach, D.N. McMuray, W.R. Jacobs Jr. J. Liu, Tuberculosis and the tubercle bacillus Emerg Infect Dis 11 2005 1331
3. A.J. Lenaerts, M.A. Degroote, and I.M. Orme Preclinical testing of new drugs for tuberculosis: current challenges Trends Microbiol 16 2008 48 54
4. S.G. Franzblau, M.A. Degroote, S.H. Cho, K. Andries, E. Nuermberger, I.M. Orme, K. Mdluli, I. Angulo-Barturen, T. Dick, V. Dartois, and A.J. Lenaerts Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis Tuberculosis (Edinb) 92 2012 453 488
5. R. Koch Aetiologie der Tuberculose Berl Klin Wochenschr 19 1882 221 230
6. A.M. Dannenberg Jr., and F.M. Collins Progressive pulmonary tuberculosis is not due to increasing numbers of viable bacilli in rabbits, mice and guinea pigs, but is due to a continuous host response to mycobacterial products Tuberculosis 81 2001 229 242
7. J.L. Flynn, S.V. Capuano, D. Croix, S. Pawar, A. Myers, A. Zinovik, and E. Klein Non-human primates: a model for tuberculosis research Tuberculosis (Edinb) 83 2003 116 118
8. U.D. Gupta, and V.M. Katoch Animal models of tuberculosis Tuberculosis 85 2005 277 293
9. R.J. Basaraba Experimental tuberculosis: the role of comparative pathology in the discovery of improved tuberculosis treatment strategies Tuberculosis 88 2008 35 47
10. S.K. Kelly, T.M. Ferney, M.T. Jessen, and I.M. Orme Low dose aerosol infection model for efficacy against Mycobacterium tuberculosis Antimicrobial Agents Chemother 40 1996 2809 2812
11. L.E. Via, P.L. Lin, S.M. Ray, J. Carrillo, S.S. Allen, S.Y. Eum, K. Taylor, E. Klein, U. Manjunatha, J. Gonzales, E.G. Lee, S.K. Part, R.A. Raleigh, S.N. Cho, D.N. Mc Murray, J.L. Flynn, and C.E. Barry III Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates Infect Immun 76 2008 2333 2340
12. D.N. McMurray Disease model: pulmonary tuberculosis Trends Mol Med 7 2001 135 137
13. G.J. Ryan, D.R. Hoff, E.R. Driver, M.I. Voskuil, M. Gonzalez-Juarrero, R.J. Basaraba, D.C. Crick, J.S. Spencer, and A.J. Lenaerts Multiple M. tuberculosis phenotypes in mouse and guinea pig lung tissue revealed by a dual-staining approach PLoS One 5 2010 e11108 10.1371/journal.pone.0011108
14. R.L. Elwood, S. Wilson, J.C. Blanco, K. Yim, L. Pletneva, B. Nikonenko, R. Samala, S. Joshi, V.G. Hemming, and M. Trucksis The American cotton rat: a novel model for pulmonary tuberculosis Tuberculosis 87 2007 145 154
15. I. Sugawara, H. Yamada, and S. Mizuno Pathological and immunological profiles of rat tuberculosis Int J Exp Pathol 85 2004 125 134
16. Singhal A, Aliouat EM, Hervé M, Mathys V, Kiass M, Creusy C, Delaire B, Tsenova L, Fleurisse L, Bertout J, Camacho L, Foo D, Tay HC, Siew JY, Boukhouchi W, Romano, M, Mathema B, Dartois V, Kaplan G, Bifani P. Experimental tuberculosis in the Wistar rat: a model for protective immunity and control of infection. PLoS ONE 2011;6:e18632. http://dx.doi.org/10.1371/journal.pone. 0018632.
17. S. Gaonkar, S. Bharath, N. Kumar, V. Balasubramanian, and R.K. Shandil Aerosol infection model of tuberculosis in Wistar rats Int J Microbiol 2010 426035. http://dx.doi.org/10.1155/2010/426035.
18. R. Jayaram, S. Gaonkar, P. Kaur, B.L. Suresh, B.N. Mahesh, R. Jayashree, V. Nandi, S. Bharat, R.K. Shandil, E. Kantharaj, and V. Balasubramanian Pharmackokinetics-pharmacodynamics of rifampicin in aerosol infection model of tuberculosis Antimicrobial Agents Chemother 47 2003 2118 2124
19. E.L. Nuermberger, T. Yoshimatsu, S. Tyagi, K. Williams, I. Rosenthal, R.J. O'Brien, A.A. Vernon, R.E. Chaisson, W.R. Bishai, and J.H. Grosset Moxifloxacin containing regimens of reduced duration produce a stable cure in murine tuberculosis Am J Respir Crit Care Med 170 2004 1131 1134
20. S. Tyagi, E. Nuermberger, T. Yoshimatsu, K. Williams, I. Rosenthal, N. Lounis, W. Bishai, and J. Grosset Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis Antimicrobial Agents Chemother 49 2005 2289 2293
21. A. Apt, and I. Kramnik Man and mouse TB: contradictions and solutions Tuberculosis 89 2009 195 198
22. A. Marry, M.A. De Groote, J.C. Gilliland, C.L. Wells, E.J. Brooks, L.K. Woolhiser, V. Gruppo, C.A. Peloquin, I.M. Orme, and A.J. Lenaerts Comparative studies evaluating mouse models use for efficacy testing of experimental drugs against M. tuberculosis Antimicrobial Agents Chemother 55 2011 1237 1247
23. L.E. Via, D.M. Weiner, D. Schimel, P.L. Lin, E. Dayao, S.L. Tankersley, Y. Cai, M.T. Coleman, J. Tomko, P. Paripati, M. Orandle, R.J. Kastenmayer, M. Tartakovsky, A. Rosenthal, D. Portevin, S.Y. Eum, S.,S. Lahouar, S. Gagneux, D.B. Young, J. Flynn, and C.E. Barry III Differential virulence and disease progression following M. tuberculosis complex infection of the Common marmoset (Callithrix jacchus) Infect Immun 81 2013 2909 2919
24. E.R. Driver, G.J. Ryan, D.R. Hoff, S.M. Irwin, R.J. Basaraba, I. Kramnik, and A.J. Lenaerts Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against M. tuberculosis Antimicrobial Agents Chemother 56 2012 3181 3195
25. H.M. Baldan, H.J. De Rosa, I.L. Brunetti, V.F. Ximenes, and R.G. Machado The effect of rifampicin and pyrazinamide on isoniazid pharmacokinetics in rats Biopharm Drug Dispos 28 2007 409 413
26. B.S. Sachin, P. Monica, S.C. Sharma, N.K. Satti, M.K. Tikoo, A.K. Tikoo, K.A. Suri, B.D. Gupta, and R.K. Johri Pharmacokinetic interaction of some antitubercular drugs with caraway: implications in the enhancement of drug bioavailability Hum Exp Toxicol 28 2009 175 184
27. B. Gold, M. Pingle, S.J. Brickner, N. Shah, J. Roberts, M. Rundell, W.C. Brackend, T. Warrier, S. Somersan, A. Venugopal, C. Darby, X. Jiang, J.D. Warren, J. Fernandez, Q. Ouerfelli, E.L. Nuermberger, A.C. Bussel, P. Rath, T. Chidawanyika, H. Deng, R. Realubit, J.F. Glickmani, and C.F. Nathan Nonsteroidal anti-inflammatory drug sensitizes M. tuberculosis to endogenous and exogenous antimicrobials Proc Natl Acad Sci U S A 109 2012 16004 16011
28. Y. Heng, P.G. Seah, J.Y. Siew, H.C. Tay, A. Singhal, V. Mathys, M. Kiass, P. Bifani, V. Dartois, and M. Hervé Mycobacterium tuberculosis infection induces hypoxic lung lesions in the rat Tuberculosis 91 2011 339 341
29. D.A. Mitchison The action of antituberculosis drugs in short course chemotherapy Tubercle 66 1985 219 225
30. R.K. Shandil, R. Jayaram, P. Kaur, S. Gaonkar, B.L. Suresh, B.N. Mahesh, R. Jayashree, V. Nandi, S. Bharath, and V. Balasubramanian Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy Antimicrobial Agents Chemother 51 2007 576 582
31. J. Rullas, J.I. García, M. Beltrán, P.J. Cardona, N. Cáceres, J.F. García-Bustos, and I. Angulo-Barturen A fast standardized therapeutic efficacy assay for drug discovery in tuberculosis Antimicrobial Agents Chemother 54 2010 2262 2264
32. S. Solapure, N. Dinesh, R.K. Shandil, V. Ramachandran, S. Sharma, D. Bhattacharjee, S. Ganguly, J. Reddy, V. Ahuja, V. Panduga, M. Parab, K.G. Vishwas, N. Kumar, M. Balganesh, and V. Balasubramanian In vitro and in vivo efficacy of beta-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis Antimicrobial Agents Chemother 57 2013 2506 2510